-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China's pharmaceutical market is huge.
With the continuous advancement of strategies such as "Healthy China 2030", the potential of China's pharmaceutical market is expected to be further released
.
In this context, multinational pharmaceutical companies are also eyeing the "big cake" of the Chinese pharmaceutical market, increasing their presence in China, and speeding up their products to the Chinese market by cooperating with local pharmaceutical companies to meet the huge problems of Chinese patients.
Meet the clinical treatment needs
.
On November 9th, Astellas and Baiyang Pharmaceutical have joined hands, and the two parties have discussed the original research drugs of Astellas Betantil (Mirabegron sustained-release tablets), Weixikang (Sorinasine succinate tablets) and The promotion and operation of Halo (tamsulosin hydrochloride sustained-release capsules) in mainland China reached a deepening cooperation agreement, which will jointly explore the commercialization of urinary treatment drugs, improve drug availability, and better serve Chinese patients with urinary diseases
.
It is understood that Betantil is mainly used for the symptomatic treatment of urinary urgency, frequent urination and/or urgency urinary incontinence in adult patients with overactive bladder (OAB)
.
Astellas was approved for listing in China in September 2018
.
According to data from Meinenet, Mirabellon’s sales in China in 2018 were 140,000 yuan, and in 2019 it rapidly increased to 5.
48 million yuan, a year-on-year increase of 3807.
39%
.
Weixikang's indications are: for the treatment of urinary incontinence and/or frequent urination and urgency in patients with overactive bladder
.
As early as 2011, Astellas' Solinasine (Weixikang) was officially listed in China
.
According to statistics from Meinenet, in 2019, the sales of Solina's new tablets in the three terminal public hospitals of cities, counties and towns in China are about 60 million yuan, and the sales in urban pharmacies are about 25 million yuan
.
Harrell indications are urination disorders caused by benign prostatic hyperplasia, which entered the Chinese market in the 1990s
.
According to data from Minai.
com, in 2017, the sales of tamsulosin hydrochloride sustained-release capsules in China's public medical institutions were 1.
095 billion yuan, of which Astellas’ tamsulosin hydrochloride sustained-release capsules accounted for most of the market share
.
Judging from the market competition pattern of these three cooperative products, the original research products are facing the impact of more and more generic drugs, and this cooperation may help Astellas increase its market share
.
According to the agreement, Baiyang Pharmaceutical will obtain the promotion and service rights of Betani and Wexikang in mainland China
.
At the same time, following Baiyang Pharmaceutical's acquisition of Harle's retail channel operation rights in mainland China in 2019, this agreement supplements other market cooperation in addition to retail channels
.
This agreement takes effect from November 9, 2021, and ends on August 31, 2026
.
It is worth mentioning that, before this, Astellas and Baiyang Pharmaceutical have cooperated on Philippine, innovative drug XOSPATA and other products to provide health services for Chinese patients in multiple disease fields
.
Among them, on December 16, 2020, Baiyang Pharmaceutical and Astellas Pharmaceuticals (China) held a signing ceremony for the cooperation intent related to XOSPATA import and general distribution
.
After the signing of the cooperation intention, the two parties will conduct further consultations on XOSPATA's integrated services such as import bonded customs clearance, warehousing and logistics, as well as omni-channel commercial platform solutions to improve the availability of medicines for adult patients with acute myeloid leukemia (AML) in China Sex
.
This time the two parties have joined hands again, which means that the cooperation will be another city, and will work together to promote the entry of urinary therapy drugs into the Chinese market, and bring more treatment options for domestic patients with urinary diseases
.
With the continuous advancement of strategies such as "Healthy China 2030", the potential of China's pharmaceutical market is expected to be further released
.
In this context, multinational pharmaceutical companies are also eyeing the "big cake" of the Chinese pharmaceutical market, increasing their presence in China, and speeding up their products to the Chinese market by cooperating with local pharmaceutical companies to meet the huge problems of Chinese patients.
Meet the clinical treatment needs
.
On November 9th, Astellas and Baiyang Pharmaceutical have joined hands, and the two parties have discussed the original research drugs of Astellas Betantil (Mirabegron sustained-release tablets), Weixikang (Sorinasine succinate tablets) and The promotion and operation of Halo (tamsulosin hydrochloride sustained-release capsules) in mainland China reached a deepening cooperation agreement, which will jointly explore the commercialization of urinary treatment drugs, improve drug availability, and better serve Chinese patients with urinary diseases
.
It is understood that Betantil is mainly used for the symptomatic treatment of urinary urgency, frequent urination and/or urgency urinary incontinence in adult patients with overactive bladder (OAB)
.
Astellas was approved for listing in China in September 2018
.
According to data from Meinenet, Mirabellon’s sales in China in 2018 were 140,000 yuan, and in 2019 it rapidly increased to 5.
48 million yuan, a year-on-year increase of 3807.
39%
.
Weixikang's indications are: for the treatment of urinary incontinence and/or frequent urination and urgency in patients with overactive bladder
.
As early as 2011, Astellas' Solinasine (Weixikang) was officially listed in China
.
According to statistics from Meinenet, in 2019, the sales of Solina's new tablets in the three terminal public hospitals of cities, counties and towns in China are about 60 million yuan, and the sales in urban pharmacies are about 25 million yuan
.
Harrell indications are urination disorders caused by benign prostatic hyperplasia, which entered the Chinese market in the 1990s
.
According to data from Minai.
com, in 2017, the sales of tamsulosin hydrochloride sustained-release capsules in China's public medical institutions were 1.
095 billion yuan, of which Astellas’ tamsulosin hydrochloride sustained-release capsules accounted for most of the market share
.
Judging from the market competition pattern of these three cooperative products, the original research products are facing the impact of more and more generic drugs, and this cooperation may help Astellas increase its market share
.
According to the agreement, Baiyang Pharmaceutical will obtain the promotion and service rights of Betani and Wexikang in mainland China
.
At the same time, following Baiyang Pharmaceutical's acquisition of Harle's retail channel operation rights in mainland China in 2019, this agreement supplements other market cooperation in addition to retail channels
.
This agreement takes effect from November 9, 2021, and ends on August 31, 2026
.
It is worth mentioning that, before this, Astellas and Baiyang Pharmaceutical have cooperated on Philippine, innovative drug XOSPATA and other products to provide health services for Chinese patients in multiple disease fields
.
Among them, on December 16, 2020, Baiyang Pharmaceutical and Astellas Pharmaceuticals (China) held a signing ceremony for the cooperation intent related to XOSPATA import and general distribution
.
After the signing of the cooperation intention, the two parties will conduct further consultations on XOSPATA's integrated services such as import bonded customs clearance, warehousing and logistics, as well as omni-channel commercial platform solutions to improve the availability of medicines for adult patients with acute myeloid leukemia (AML) in China Sex
.
This time the two parties have joined hands again, which means that the cooperation will be another city, and will work together to promote the entry of urinary therapy drugs into the Chinese market, and bring more treatment options for domestic patients with urinary diseases
.
